Please assess the completion status of the following clinical trial:

Trial Title: Death to Onchocerciasis and Lymphatic Filariasis (DOLF) Triple Drug Therapy for Lymphatic Filariasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
In India:~Inclusion Criteria:~1. Age ≥ 5 years, male or female for IDA arm and age \> 2 years for DA arm.~2. Able to provide informed consent to participate in the trial (forms to be attached)~3. No evidence of severe or systemic co-morbidities except for features of filarial disease~Exclusion Criteria:~1. Age \< 5 years (ivermectin is contraindicated in children below 5 years of age) for IDA arm and age \< 2 years for DA arm~2. Pregnant women (DEC, ivermectin and albendazole are contraindicated in pregnancy)~3. Severe chronic illness (for example, chronic renal failure, inability to care for oneself with activities of daily living)~4. History of previous allergy to MDA drugs~For rest of countries:~Inclusion Criteria:~1. Age ≥ 5 years, for IDA and DA arms (males and females).~2. Able to provide informed consent or give parental consent for minors to participate in the trial~3. No evidence of severe or systemic co-morbidities except for features of filarial disease~Exclusion Criteria:~1. Age \< 5 years (ivermectin is not approved for use in children less than 5 years of age)~2. Unable to provide informed consent or give parental consent for minors to participate in the trial~3. Pregnant women (DEC, ivermectin and albendazole are not known to be safe for use during pregnancy)~4. Severe chronic illness (chronic renal insufficiency, severe chronic liver disease, or any illness that is severe enough to interfere with activities of daily living)~5. History of previous allergy to MDA drugs

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 2 drug dose - DA (Type: ACTIVE_COMPARATOR): Drug treatment with two-drug regimen diethylcarbamazine and albendazole (DA)
- 3 drug dose - IDA (Type: EXPERIMENTAL): Triple-drug regimen Ivermectin, diethylcarbamazine and albendazole (IDA)

Based on this trial design, predict the completion outcome and termination type (if applicable).